Navana Pharmaceuticals PLC (DSE:NAVANAPHAR)
Bangladesh
· Delayed Price · Currency is BDT 48.60
+0.20 (0.41%)
At close: Jun 4, 2025
Navana Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 |
| Revenue | 8,470 | 6,898 | 5,706 | 4,759 | 3,607 | 3,149 |
| Revenue Growth (YoY) | 30.23% | 20.89% | 19.91% | 31.95% | 14.53% | - |
| Cost of Revenue | 4,600 | 3,770 | 3,110 | 2,599 | 1,993 | 1,740 |
| Gross Profit | 3,870 | 3,128 | 2,596 | 2,160 | 1,614 | 1,409 |
| Selling, General & Admin | 2,522 | 2,136 | 1,841 | 1,591 | 1,265 | 1,135 |
| Operating Expenses | 2,522 | 2,136 | 1,841 | 1,591 | 1,265 | 1,135 |
| Operating Income | 1,348 | 991.84 | 755.72 | 569.6 | 348.59 | 274.18 |
| Interest Expense | -734.21 | -463.57 | -234.89 | -200.42 | -75.18 | -91.59 |
| Interest & Investment Income | 1.87 | 1.47 | 5.84 | 5.58 | 0.03 | 0.04 |
| Currency Exchange Gain (Loss) | -39.44 | -25.18 | -33.38 | -93.98 | -2.52 | -5.11 |
| Other Non Operating Income (Expenses) | 13.92 | 11.39 | -1.91 | 27.64 | 30.47 | 22.09 |
| EBT Excluding Unusual Items | 590.58 | 515.95 | 491.38 | 308.42 | 301.39 | 199.6 |
| Gain (Loss) on Sale of Investments | -12.31 | -0.88 | -42.3 | 82.9 | - | 19.68 |
| Gain (Loss) on Sale of Assets | -0.36 | 1.18 | - | 0.47 | 1.02 | - |
| Pretax Income | 577.92 | 516.25 | 449.08 | 391.79 | 302.41 | 219.28 |
| Income Tax Expense | 129.95 | 111.62 | 92.14 | 117.78 | 100.12 | 81.88 |
| Net Income | 447.97 | 404.63 | 356.94 | 274 | 202.29 | 137.4 |
| Net Income to Common | 447.97 | 404.63 | 356.94 | 274 | 202.29 | 137.4 |
| Net Income Growth | 1.81% | 13.36% | 30.27% | 35.45% | 47.23% | - |
| Shares Outstanding (Basic) | 107 | 107 | 99 | 80 | 80 | 80 |
| Shares Outstanding (Diluted) | 107 | 107 | 99 | 80 | 80 | 80 |
| Shares Change (YoY) | -0.12% | 8.05% | 23.91% | - | - | - |
| EPS (Basic) | 4.17 | 3.77 | 3.59 | 3.42 | 2.52 | 1.71 |
| EPS (Diluted) | 4.17 | 3.77 | 3.59 | 3.42 | 2.52 | 1.71 |
| EPS Growth | 1.93% | 4.92% | 5.13% | 35.45% | 47.23% | - |
| Free Cash Flow | 528.31 | -625.1 | -1,404 | -1,160 | -399 | 181.8 |
| Free Cash Flow Per Share | 4.92 | -5.82 | -14.13 | -14.45 | -4.97 | 2.27 |
| Dividend Per Share | 1.400 | 1.400 | 1.300 | 1.100 | - | - |
| Dividend Growth | 7.69% | 7.69% | 18.18% | - | - | - |
| Gross Margin | 45.69% | 45.34% | 45.50% | 45.39% | 44.75% | 44.73% |
| Operating Margin | 15.92% | 14.38% | 13.24% | 11.97% | 9.66% | 8.71% |
| Profit Margin | 5.29% | 5.87% | 6.25% | 5.76% | 5.61% | 4.36% |
| Free Cash Flow Margin | 6.24% | -9.06% | -24.61% | -24.37% | -11.06% | 5.77% |
| EBITDA | 1,522 | 1,163 | 966.13 | 675.37 | 397.71 | 314.49 |
| EBITDA Margin | 17.97% | 16.86% | 16.93% | 14.19% | 11.03% | 9.99% |
| D&A For EBITDA | 173.97 | 171.25 | 210.41 | 105.77 | 49.12 | 40.31 |
| EBIT | 1,348 | 991.84 | 755.72 | 569.6 | 348.59 | 274.18 |
| EBIT Margin | 15.92% | 14.38% | 13.24% | 11.97% | 9.66% | 8.71% |
| Effective Tax Rate | 22.48% | 21.62% | 20.52% | 30.06% | 33.11% | 37.34% |
| Advertising Expenses | - | 38.4 | 33.13 | 80.86 | 19.55 | 16.63 |
Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.